TY - JOUR
T1 - Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease
T2 - A Nationwide Population-based Study in Taiwan
AU - Wang, Li Hui
AU - Yang, Yao Jong
AU - Cheng, Wei Chun
AU - Wang, Wei Ming
AU - Lin, Sheng Hsiang
AU - Shieh, Chi Chang
N1 - Publisher Copyright:
© 2016 by the American College of Gastroenterology.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Objectives: The relationship between inflammatory bowel disease (IBD) and cancer remains unclear especially in Asian populations. Therefore, we conducted a nationwide population-based study in Taiwan to reveal the cancer risk in patients with IBD. Methods: Using the national health database of Taiwan, we identified 3,348 IBD patients without previous cancer, including 685 with Crohn's disease (CD) and 2,663 with ulcerative colitis (UC), as a cohort from 1998 to 2012 and followed them up until 2013. Standardized incidence ratios (SIRs) of overall and site-specific cancers in CD and UC patients in comparison with the general population were analyzed. Results: Regarding overall cancer risk analysis, both CD (SIR 1.4, 95% confidence interval (CI) 0.9-2.1) and UC (SIR 0.93, 95% CI 0.7-1.1) patients did not have a higher risk. In site-specific cancer risk analysis, CD (SIR 14.08, P<0.01) and UC (SIR 2.51, P=0.02) patients had a higher risk of hematological malignancies. The risk of colorectal cancer (CRC) did not increase significantly in either CD (SIR 0.96, P=0.7) or UC (SIR 1.39, P=0.22) patients. Conclusions: This first nationwide population-based study in Asia reveals a significantly higher risk for hematological malignancies in IBD patients. This finding may highlight the importance of screening for hematological malignancies in patients with IBD in the future.
AB - Objectives: The relationship between inflammatory bowel disease (IBD) and cancer remains unclear especially in Asian populations. Therefore, we conducted a nationwide population-based study in Taiwan to reveal the cancer risk in patients with IBD. Methods: Using the national health database of Taiwan, we identified 3,348 IBD patients without previous cancer, including 685 with Crohn's disease (CD) and 2,663 with ulcerative colitis (UC), as a cohort from 1998 to 2012 and followed them up until 2013. Standardized incidence ratios (SIRs) of overall and site-specific cancers in CD and UC patients in comparison with the general population were analyzed. Results: Regarding overall cancer risk analysis, both CD (SIR 1.4, 95% confidence interval (CI) 0.9-2.1) and UC (SIR 0.93, 95% CI 0.7-1.1) patients did not have a higher risk. In site-specific cancer risk analysis, CD (SIR 14.08, P<0.01) and UC (SIR 2.51, P=0.02) patients had a higher risk of hematological malignancies. The risk of colorectal cancer (CRC) did not increase significantly in either CD (SIR 0.96, P=0.7) or UC (SIR 1.39, P=0.22) patients. Conclusions: This first nationwide population-based study in Asia reveals a significantly higher risk for hematological malignancies in IBD patients. This finding may highlight the importance of screening for hematological malignancies in patients with IBD in the future.
UR - http://www.scopus.com/inward/record.url?scp=84984870540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984870540&partnerID=8YFLogxK
U2 - 10.1038/ajg.2016.239
DO - 10.1038/ajg.2016.239
M3 - Article
C2 - 27296944
AN - SCOPUS:84984870540
SN - 0002-9270
VL - 111
SP - 1313
EP - 1319
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 9
ER -
